Insider Transactions in Q4 2024 at Aclaris Therapeutics, Inc. (ACRS)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2024
|
Joseph Monahan Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
15,000
-8.03%
|
-
|
|
Dec 04
2024
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
68,343
-4.55%
|
$205,029
$3.76 P/Share
|
|
Dec 04
2024
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
118,840
+7.33%
|
$118,840
$1.52 P/Share
|
|
Dec 01
2024
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,721
-0.2%
|
$10,884
$4.07 P/Share
|
|
Dec 01
2024
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,466
+0.68%
|
-
|
|
Nov 19
2024
|
Anand Mehra |
BUY
Open market or private purchase
|
Direct |
666,666
+48.43%
|
$1,333,332
$2.25 P/Share
|
|
Nov 01
2024
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,721
-0.2%
|
$5,442
$2.09 P/Share
|
|
Nov 01
2024
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,467
+0.68%
|
-
|
|
Oct 01
2024
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,722
-0.2%
|
$2,722
$1.18 P/Share
|
|
Oct 01
2024
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,467
+0.69%
|
-
|